Electronic NDA Requirement Should Be Phased In Over 3 Years, Small Firms Say

Small pharmaceutical companies favor FDA's proposal to move from paper to electronic filing of regulatory submissions but want a three-year grace period following the agency's issuance of a final rule

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet